Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by equities research analysts at J P Morgan Chase & Co from a “neutral” rating to an “underweight” rating in a note issued to investors on Monday, Marketbeat Ratings reports. They presently have a $11.00 target price on the stock, down from their prior target price of $11.48. J P Morgan Chase & Co’s price objective would indicate a potential downside of 5.34% from the company’s current price.
Other research analysts also recently issued reports about the company. Credit Suisse Group set a $39.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price target on the stock in a research note on Monday, July 24th. Deutsche Bank AG reiterated a “buy” rating and issued a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. BTIG Research upgraded Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Monday, September 11th. Finally, Gabelli reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, September 13th. Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $22.29.
Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down $0.16 during midday trading on Monday, reaching $11.62. The company’s stock had a trading volume of 9,255,253 shares, compared to its average volume of 15,166,499. Teva Pharmaceutical Industries Limited has a 12-month low of $10.85 and a 12-month high of $41.19. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The firm has a market cap of $11,860.00, a price-to-earnings ratio of 2.72 and a beta of 0.52.
ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Downgraded by J P Morgan Chase & Co to “Underweight”” was published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/13/j-p-morgan-chase-co-downgrades-teva-pharmaceutical-industries-limited-teva-to-underweight.html.
Several hedge funds have recently modified their holdings of the business. Xact Kapitalforvaltning AB acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter valued at $269,000. Capital One National Association bought a new position in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter worth about $265,000. Chevy Chase Trust Holdings Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 7.5% in the 2nd quarter. Chevy Chase Trust Holdings Inc. now owns 6,742 shares of the company’s stock worth $224,000 after acquiring an additional 469 shares in the last quarter. Eqis Capital Management Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 12.8% in the 2nd quarter. Eqis Capital Management Inc. now owns 10,967 shares of the company’s stock worth $364,000 after acquiring an additional 1,246 shares in the last quarter. Finally, OLD National Bancorp IN bought a new stake in Teva Pharmaceutical Industries Limited in the 2nd quarter valued at about $329,000. 55.81% of the stock is currently owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.